Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
BIOAthis companyBioAge Labs Inc.	$5.43	-5.91×	1.75×	52.85×	-3.66×	53.5%	100.0%	-1031.5%	-896.1%	-29.6%	-33.4%	-17.3%	0.02×	2.3×	-133.11×	14.24×	0.0%	3	4.79	2	C+
ALLOAllogene Therapeutics, Inc.	$1.02	-1.57×	1.03×	0×	-1.88×	-114.2%	0.0%	0.0%	0.0%	-65.3%	-52.8%	-49.5%	0.28×	-0.18×	-192.5×	7.93×	0.0%	4	-3.65	2	C
AVIRAtea Pharmaceuticals, Inc.	$4.40	-1.84×	1.06×	0×	-1.19×	-75.3%	0.0%	0.0%	0.0%	-57.5%	-63.0%	-45.4%	0×	0.58×	0×	7.82×	0.0%	2	1.99	3	B-
CABACabaletta Bio, Inc.	$1.47	-1.34×	2×	0×	-1.02×	-65.7%	0.0%	0.0%	0.0%	-149.8%	-123.8%	-59.1%	0.24×	0.34×	-85.95×	2.77×	0.0%	2	-1.41	2	C+
EDITEditas Medicine, Inc.	$2.72	-1.14×	6.67×	4.49×	-0.75×	-308.6%	100.0%	-245.2%	-395.0%	-586.6%	-65.6%	-91.2%	2.81×	0.47×	-16.1×	3.54×	0.0%	3	-8.13	2	C
HUMAHumacyte, Inc.	$0.48	-3.69×	48.86×	74.54×	-7.48×	-105.8%	-736.5%	-5271.7%	-2003.6%	-1313.4%	-107.0%	-69.7%	20.86×	-0.65×	-9.55×	3.69×	0.0%	3	-8.67	1	D+
Peer median	—	-1.57×	2×	0×	-1.19×	-105.8%	0.0%	0.0%	0.0%	-149.8%	-65.6%	-59.1%	0.28×	0.34×	-16.1×	3.69×	0.0%	3	-3.65	2	—